These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 16086597)
41. The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. Peyrani P; Mandell L; Torres A; Tillotson GS Expert Rev Respir Med; 2019 Feb; 13(2):139-152. PubMed ID: 30596308 [TBL] [Abstract][Full Text] [Related]
42. Community-acquired pneumonia. Diagnostic and therapeutic approach. Cunha BA Med Clin North Am; 2001 Jan; 85(1):43-77. PubMed ID: 11190352 [TBL] [Abstract][Full Text] [Related]
43. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. El Moussaoui R; Opmeer BC; de Borgie CA; Nieuwkerk P; Bossuyt PM; Speelman P; Prins JM Chest; 2006 Oct; 130(4):1165-72. PubMed ID: 17035452 [TBL] [Abstract][Full Text] [Related]
44. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed? Cunha BA Chest; 2004 May; 125(5):1913-9. PubMed ID: 15136407 [TBL] [Abstract][Full Text] [Related]
45. [Reducing the duration of antibiotic therapy in acute community-acquired pneumonia]. Groupe Entretiens du Club de réflexion sur l'infection respiratoire Rev Pneumol Clin; 2008 Feb; 64(1):3-7. PubMed ID: 18603172 [TBL] [Abstract][Full Text] [Related]
47. Duration of antimicrobial therapy for nosocomial pneumonia: possible strategies for minimizing antimicrobial use in intensive care units. Dugan HA; MacLaren R; Jung R J Clin Pharm Ther; 2003 Apr; 28(2):123-9. PubMed ID: 12713609 [TBL] [Abstract][Full Text] [Related]
48. Impact of an antimicrobial stewardship program on outcomes in patients with community-acquired pneumonia admitted to a tertiary community hospital. Gordon K; Stevens R; Westley B; Bulkow L Am J Health Syst Pharm; 2018 Jun; 75(11 Supplement 2):S42-S50. PubMed ID: 29802178 [TBL] [Abstract][Full Text] [Related]
49. How to reduce antibiotic consumption for community-acquired pneumonia? Montassier E; Goffinet N; Potel G; Batard E Med Mal Infect; 2013 Feb; 43(2):52-9. PubMed ID: 23433607 [TBL] [Abstract][Full Text] [Related]
50. Community acquired pneumonia. Al-Qadi MO; Al-Alwan A; Opal SM; Cillley B; Silverblatt FJ Med Health R I; 2010 Jul; 93(7):196-200. PubMed ID: 20707009 [No Abstract] [Full Text] [Related]
51. Levofloxacin in the treatment of community-acquired pneumonia. Noreddin AM; Elkhatib WF Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679 [TBL] [Abstract][Full Text] [Related]
52. Short-course antimicrobial therapy for paediatric respiratory infections (SAFER): study protocol for a randomized controlled trial. Pernica J; Harman S; Kam A; Bailey J; Carciumaru R; Khan S; Fulford M; Thabane L; Slinger R; Main C; Smieja M; Loeb M Trials; 2018 Feb; 19(1):83. PubMed ID: 29391051 [TBL] [Abstract][Full Text] [Related]
53. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768 [TBL] [Abstract][Full Text] [Related]
54. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679 [TBL] [Abstract][Full Text] [Related]
55. Antibiotic therapy for inpatients with community-acquired pneumonia in a developing country. Trinh HT; Hoang PH; Cardona-Morrell M; Nguyen HT; Vu DH; Dong PT; Cao TT; Nguyen ST; Pham VT; Moss L; Dinh K; Dartnell J; Nguyen HT Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):129-36. PubMed ID: 24648269 [TBL] [Abstract][Full Text] [Related]
56. Can an antimicrobial stewardship program reduce length of stay of immune-competent adult patients admitted to hospital with diagnosis of community-acquired pneumonia? Study protocol for pragmatic controlled non-randomized clinical study. DiDiodato G; McArthur L; Beyene J; Smieja M; Thabane L Trials; 2015 Aug; 16():355. PubMed ID: 26272324 [TBL] [Abstract][Full Text] [Related]
57. Short-duration therapy for respiratory tract infections. Goff DA Ann Pharmacother; 2004 Sep; 38(9 Suppl):S19-23. PubMed ID: 15226490 [TBL] [Abstract][Full Text] [Related]
58. How short can courses be in lower respiratory tract infections? Siegel R J Int Med Res; 2000; 28 Suppl 1():37A-47A. PubMed ID: 11092228 [TBL] [Abstract][Full Text] [Related]
59. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. Kuzman I; Daković-Rode O; Oremus M; Banaszak AM J Chemother; 2005 Dec; 17(6):636-42. PubMed ID: 16433194 [TBL] [Abstract][Full Text] [Related]
60. Application of antimicrobial stewardship to optimise management of community acquired pneumonia. Bosso JA; Drew RH Int J Clin Pract; 2011 Jul; 65(7):775-83. PubMed ID: 21676120 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]